Jazz Pharma down 9% after hours on Q1 miss, guidance cut

Jazz Pharmaceuticals (NASDAQ:JAZZ) Q1 results:

Revenues: $534.7M (+5.2%); product sales: $530.2M (+5.3%).

Xyrem sales: $407.9M (+10.8%); Defitelio/defibrotide: $47.4M (+14.2%); Erwinaze: $37.7M (-38.1%).

Net loss: ($157.8M) (-285.2%); non-GAAP net income: $25.8M (-84.3%); loss/share: ($2.82) (-291.8%); non-GAAP EPS: $0.45 (-84.1%).

~1.1M ordinary shares repurchased at an average price of $122.91.

2020 guidance: Revenues: $2,120M – 2,260M from $2,320M – 2,400M; product sales: $2,105M – 2,240M from $2,305M – 2,375M; sleep/neuroscience sales: $1,650M – 1,740M from $1,740M – 1,810M; hematology/oncology sales: $420M – 510M from $500M – 580M.

Shares down 9% after hours.

Jazz Pharmaceuticals EPS misses by $0.38, misses on revenue

https://seekingalpha.com/news/3569640-jazz-pharma-down-9-after-hours-on-q1-miss-guidance-cut